MNG81
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.411
- OXIDATIVE_PHOSPHORYLATION+0.411
- MYC_TARGETS_V1+0.400
- E2F_TARGETS+0.324
- G2M_CHECKPOINT+0.245
- SPERMATOGENESIS+0.108
- UNFOLDED_PROTEIN_RESPONSE+0.077
- GLYCOLYSIS+0.071
- FATTY_ACID_METABOLISM+0.065
- DNA_REPAIR+0.042
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.498
- IL6_JAK_STAT3_SIGNALING-0.461
- APOPTOSIS-0.440
- CHOLESTEROL_HOMEOSTASIS-0.435
- INFLAMMATORY_RESPONSE-0.407
- COMPLEMENT-0.406
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.402
- ALLOGRAFT_REJECTION-0.389
- KRAS_SIGNALING_UP-0.386
- INTERFERON_GAMMA_RESPONSE-0.374
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG82 | — | — | 0.996 |
| 2 | ERR2208947 | — | — | 0.932 |
| 3 | SAMN03290897 | — | — | 0.925 |
| 4 | TCGA-CV-6948-01A-11R-1915-07 | — | — | 0.913 |
| 5 | BS_2A5R9MEJ | high-grade glioma | — | 0.905 |
| 6 | SAMN03290891 | — | — | 0.896 |
| 7 | SRR8518243 | — | E | 0.896 |
| 8 | BS_9NJHQE9F | medulloblastoma | — | 0.895 |
| 9 | SRR2777976 | — | — | 0.894 |
| 10 | MNG87 | — | — | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.411 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.411 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.324 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.245 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.108 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.077 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.071 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.065 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.042 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.002 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.001 | Inavolisib | — uncovered |